Post-Stroke Recrudescence in the Setting of Tramadol Overuse:
A Case Report
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Introduction

Case Report (cont.)

Discussion (cont.)

- Recrudescence is the recurrence of symptoms of a condition
thought to have resolved. In the case of stroke, focal
neurological symptoms can recrudesce years after patients
recover from stroke.

- Both CT and MRI without contrast showed brain findings
consistent with a large, old right middle cerebral artery
(RMCA) infarct, but no acute abnormalities (Figure 1).
Previous head imaging was not available for comparison.

- Mechanisms behind opioid-induced PSR remain poorly
understood. Some propose that opioids’ activation of muopioid receptors blocks downstream activation of cortical
NMDA and AMPA receptors important to the neurogenesis
and stability of compensatory neural networks.5

- Metabolic, infectious, and substance-related causes can all
contribute to post-stroke recrudescence (PSR).1,2 Substance
use merits more extensive analysis as a cause due to the USwide opioid crisis.
- Since the mid-1990s, when Purdue Pharma L.P., the care
standard-setting Joint Commission, and other interest
groups pushed for physicians’ increased prescription of
opioids in pain relief, US opioid-related addiction,
morbidity, and mortality have steadily increased.3 2017 saw
over 28,000 US, synthetic opioid overdose-related deaths.4

Case Report
- A 76-year-old woman presented to the hospital for 3 days of
left-sided weakness.
- Symptoms, which began while she was at her retirement
home, included left-sided facial droop, slurred speech, and
inability to raise her left arm. Neither she nor family
recalled similar previous symptoms, or inciting factors.
- The patient was somnolent but arousable. At the ED earlier,
doses of IM naloxone had temporarily improved her mental
status. Nursing home staff reported she had regularly been
taking 50 mg oral tramadol every 6 hours for fall-related
shoulder and leg pain.
- Other conditions included well-managed ESRD on dialysis,
hypertension, hyperlipidemia, and type II diabetes.
- Vital signs remained within normal limits. Physical exam
was notable for small pupils and lacrimation, and confirmed
the patient’s described left-sided weakness.
- Panels showed no notable electrolyte or vitamin
abnormalities. Standard urine drug screen (UDS) was
negative. However, urine studies revealed cloudy urine with
+3 leukocyte esterase, +2 bacteria, and numerous WBCs.

- The patient’s sex and medical conditions constituted
vascular risk factors for PSR. Studies also suggest MCA
territory infarcts as highest risk for PSR.2,5 Potentially, MCA
infarct discovery could prompt more stringent efforts by
providers and patients to avoid common PSR triggers.
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Figure 1: Transverse and coronal MRI views of the brain were
unremarkable for acute pathology, but showed cortical laminar necrosis
in the right temporoparietal lobe (arrows), and ex vacuo dilatation of
right occipital and temporal horns consistent with an old RMCA infarct.

- Assessment was concerning for post-stroke recrudescence
due to tramadol use and, to a lesser extent, UTI. Tramadol
was discontinued and replaced with acetaminophen for
pain relief. UTI was managed with IV ceftriaxone, later
converted to oral amoxicillin-clavulanate.
- Further discussion with nursing home staff suggested the
patient may have been taking extra, non-scheduled
tramadol prior to onset of symptoms.
- 72 hours into her stay, and post-discontinuation of
tramadol, the patient’s weakness symptoms largely
resolved. She was discharged and driven to a nearby
skilled nursing facility where she completed her recovery.

L- Initial workup had both a negative UDS and lack of patient

recollection of past strokes. A synthetic opioid, tramadol can
evade standard tests that detect other opioids.6 Patients also
understandably may not recall earlier conditions, especially
when memory is impacted by neurologic events. Misleading
initial findings about negative drug and stroke history were
rectified by collateral histories and brain imaging. This case
highlights the importance of subjective and objective workup to cover each other’s limitations in attaining a diagnosis.

Conclusion
This report promotes greater awareness of opioid-induced
PSR, especially considering the tragic opioid crisis that has
afflicted the US since the 1990s, and the contribution of
synthetic prescription opioids to the crisis. This report also
supports the establishment of care guidelines to limit PSR risk
in people with major risk factors, such as MCA infarcts.
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